A patient with multiple myeloma receiving daratumumab (anti-CD38) has weak panreactivity with all screening and panel cells at the antiglobulin phase. When the reagent cells are treated with 0.2 M dithiothreitol (DTT), all reactions become negative. The patient's K antigen status is K-negative. Which red cell selection is most appropriate?
1Antiglobulin-crossmatch-compatible units that are also Fy(a-)
2Antiglobulin-crossmatch-compatible units that are also Jk(a-)
3Antiglobulin-crossmatch-compatible units that are also K-negative✓ 정답
4Antiglobulin-crossmatch-compatible units that are also e-negative
해설
DTT denatures CD38 on reagent cells and removes daratumumab interference, but it also destroys Kell system antigens, so anti-K cannot be excluded with DTT-treated cells. A K-negative patient is therefore given K-negative units; Duffy, Kidd, and Rh antigens survive DTT and those antibodies are still excluded by the DTT-treated panel.